Related Experiment Videos
Prostaglandin E1 therapy of murine chronic serum sickness
Abstract:
We studied the effect of PGE1 in pharmacologic doses on immune complex-induced glomerulonephritis produced by daily intraperitoneal injections of apoferritin. Mice received one of the following injection schedules: apoferritin 4 mg/day, apoferritin 4 mg/day plus PGE1 200 microgram twice daily, saline, or PGE1 200 microgram twice daily. Administration of apoferritin alone resulted in mesangial cell proliferation in all 14 mice with crescent formation in nine. Evidence of subepithelial and mesangial immune complex deposition and a significant increase in urine protein excretion was found. Treatment with PGE1 resulted in a mild increase in mesangial cells in six of 14 mice. No mice developed crescents on this regimen. In addition, proteinuria was prevented, and there was a marked diminution of immune complex deposition. Antiapoferritin antibody was detected in the sera of mice from both groups. No alteration in lymphocyte response to mitogen or in vitro PGE1 suppression of blastogenesis was detected. Our results indicate that PGE1 therapy alters immune complex glomerulonephritis in this model of murine chronic serum sickness by reducing glomerular immune complex deposition. However, no difference in specific or nonspecific immunologic responses was detected.
Insights
Prostaglandin E1 (PGE1) therapy effectively reduced immune complex deposition in mice with glomerulonephritis. This treatment prevented proteinuria and crescent formation, offering a potential therapeutic strategy for kidney disease.
Area of Science:
- Nephrology
- Immunology
- Pharmacology
Background:
- Immune complex-induced glomerulonephritis is a significant cause of kidney disease.
- Understanding therapeutic interventions for this condition is crucial.
Purpose of the Study:
- To investigate the therapeutic effects of Prostaglandin E1 (PGE1) on immune complex-induced glomerulonephritis in a murine model.
- To assess PGE1's impact on glomerular immune complex deposition, kidney function, and immune responses.
Main Methods:
- A mouse model of chronic serum sickness was established using daily intraperitoneal injections of apoferritin.
- Mice were treated with either apoferritin alone, apoferritin plus PGE1, saline, or PGE1 alone.
- Kidney pathology, immune complex deposition, proteinuria, and immunological parameters were evaluated.
Main Results:
- Apoferritin administration induced mesangial cell proliferation, crescent formation, and significant proteinuria.
- PGE1 treatment markedly reduced glomerular immune complex deposition and prevented proteinuria and crescent formation.
- No significant alterations were observed in lymphocyte responses to mitogens or PGE1's in vitro suppression of blastogenesis.
Conclusions:
- PGE1 therapy demonstrates a protective effect against immune complex-induced glomerulonephritis in this murine model.
- The therapeutic benefit appears to be mediated by reduced glomerular immune complex deposition, not by altering systemic immune responses.